These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30615503)

  • 1. Letter by Potier and Roussel Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes".
    Potier L; Roussel R
    Circulation; 2019 Jan; 139(2):303-304. PubMed ID: 30615503
    [No Abstract]   [Full Text] [Related]  

  • 2. Response by Nassif and Kosiborod to Letter Regarding Article, "Are We Ready to Bell the Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes".
    Nassif ME; Kosiborod M
    Circulation; 2019 Jan; 139(2):305-306. PubMed ID: 30615504
    [No Abstract]   [Full Text] [Related]  

  • 3. Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.
    Nassif ME; Kosiborod M
    Circulation; 2018 Jul; 138(1):4-6. PubMed ID: 29967227
    [No Abstract]   [Full Text] [Related]  

  • 4. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letter by Tampaki et al Regarding Article, "Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors".
    Tampaki EC; Tampakis A; Gürke L; Pantos C
    Circ Res; 2018 Aug; 123(4):e1-e2. PubMed ID: 30355254
    [No Abstract]   [Full Text] [Related]  

  • 6. Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.
    Vardeny O; Vaduganathan M
    JACC Heart Fail; 2019 Feb; 7(2):169-172. PubMed ID: 30704605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
    Inoue D; Nishi H; Inoue R; Nangaku M
    Int Heart J; 2021; 62(3):592-600. PubMed ID: 34054000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
    Nelson AJ; Pagidipati NJ; Aroda VR; Cavender MA; Green JB; Lopes RD; Al-Khalidi H; Gaynor T; Kaltenbach LA; Kirk JK; Lingvay I; Magwire ML; O'Brien EC; Pak J; Pop-Busui R; Richardson CR; Reed M; Senyucel C; Webb L; McGuire DK; Granger CB
    Circulation; 2021 Jul; 144(1):74-84. PubMed ID: 34228476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging glucose-lowering therapies: a guide for cardiologists.
    Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
    Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".
    Koh KK
    Circulation; 2018 Feb; 137(9):984-985. PubMed ID: 29483177
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".
    Taegtmeyer H; Karlstaedt A
    Circulation; 2018 Feb; 137(9):986-987. PubMed ID: 29483178
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter by Tampaki et al Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".
    Tampaki EC; Tampakis A; Pantos C
    Circulation; 2018 Feb; 137(9):982-983. PubMed ID: 29483176
    [No Abstract]   [Full Text] [Related]  

  • 13. SGLT2 inhibitors: practical considerations and recommendations for cardiologists.
    Opingari E; Partridge ACR; Verma S; Bajaj HS
    Curr Opin Cardiol; 2018 Nov; 33(6):676-682. PubMed ID: 30148719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist".
    Matthews DR; Perkovic V; Mahaffey KW
    Circulation; 2018 Aug; 138(6):660-661. PubMed ID: 30354619
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
    Forst T; Plum-Mörschel L; Weber MM
    Internist (Berl); 2017 Mar; 58(3):293-302. PubMed ID: 28120022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of diabetes and heart failure: a paradigm shift for cardiologists?
    Brochu B; Chan M
    Curr Opin Cardiol; 2019 Mar; 34(2):207-212. PubMed ID: 30608252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes.
    Rocha N; Das SR
    J Diabetes; 2019 Jul; 11(7):605-609. PubMed ID: 31044534
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter by Jin-shan and Xue-bin Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".
    Jin-Shan H; Xue-Bin L
    Circulation; 2018 Feb; 137(9):988. PubMed ID: 29483179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.